96-28579. Settlement of Scientific Misconduct Allegations

[Federal Register Volume 61, Number 216 (Wednesday, November 6, 1996)]
[Notices]
[Page 57436]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-28579]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Settlement of Scientific Misconduct Allegations

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case of alleged 
scientific misconduct:
    Gang Yuan, Fox Chase Cancer Center: The Office of Research 
Integrity (ORI) has entered into a Voluntary Exclusion Agreement with 
Mr. Gang Yuan, a former laboratory technician at the Fox Chase Cancer 
Center (FCCC). This agreement was based on information obtained by ORI 
during its oversight review of an investigation conducted by FCCC into 
allegations of scientific misconduct made against Mr. Yuan. ORI's 
oversight review focused on the issue of falsification of research 
results by the insertion of allegedly false data into a computer-based 
formula and then back-calculation to support the falsified results. The 
data at issue involved research supported by Public Health Service 
(PHS) grants and was included in a grant application submitted to the 
National Institute of General Medical Sciences (NIGMS) and in a 
manuscript submitted to but not published by the journal Biochemistry.
    Although Mr. Yuan disagreed with the allegations and ORI's proposed 
administrative actions, to resolve the matter, Mr. Yuan has voluntarily 
agreed, for the two (2) year period beginning October 25, 1996, to 
voluntarily exclude himself from:
    (1) any contracting or subcontracting with any agency of the United 
States Government and from eligibility for, or involvement in, 
nonprocurement transactions (e.g., grants and cooperative agreements) 
of the United States Government as defined in 45 C.F.R. Part 76 
(Debarment Regulations); and
    (2) serving in any advisory capacity to PHS, including but not 
limited to service on any PHS advisory committee, board, and/or peer 
review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research 
Investigations, Office of Research Integrity, 5515 Security Lane, Suite 
700, Rockville, MD 20852, 301 443-5330.
Chris B. Pascal,
Acting Director, Office of Research Integrity.
[FR Doc. 96-28579 Filed 11-5-96; 8:45 am]
BILLING CODE 4160-17-P